HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2516922122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Juan Yuan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm 171 77, Sweden. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Basic Helix-Loop-Helix Proteins, Adrenergic Neurons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barncancerfonden (Swedish Childhood Cancer Foundation), Cancerfonden (Swedish Cancer Society), Vetenskapsrådet (VR).
Abstract (Originalsprache)
The role of HIF2α, encoded by EPAS1 , in neuroblastoma remains controversial. Here, we demonstrate that induction of high levels of HIF2α in MYCN-amplified neuroblastoma cells results in a rapid and profound reduction of the oncoprotein MYCN. This is followed by an upregulation of genes characteristic of noradrenergic cells in the adrenal medulla. Additionally, upon induction of HIF2α, the proliferation rate drops substantially, and cells develop elongated neurite-like protrusions, indicative of differentiation. In vivo HIF2α induction in established xenografts significantly attenuates tumor growth. Notably, analysis of sequenced neuroblastoma patient samples, revealed a negative correlation between EPAS1 and MYCN expression and a strong positive correlation between EPAS1 expression, high expression levels of noradrenergic markers, and improved patient outcome. This was paralleled by analysis of human developing adrenal medulla datasets wherein EPAS1 expression was prominent in populations with high expression levels of genes characteristic of noradrenergic chromaffin cells. Our findings show that high levels of HIF2α in neuroblastoma, leads to drastically reduced MYCN protein levels, cell cycle exit, and noradrenergic cell differentiation. Taken together, our results challenge the dogma that HIF2α acts as an oncogene in neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm 171 77, Sweden.
- Department of Molecular Biology, Umeå University, Umeå 901 87, Sweden.
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm 171 77, Sweden.
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm 171 65, Sweden.
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm 171 65, Sweden.
- School of Medical Sciences, University of Örebro, Örebro 701 82, Sweden.
ORCID-Profile: Eirini Antoniou, Iria Laura Martinez, Lacin Ozcimen, Henrik Lindehell, Jonas Muhr, Per Kogner, Oscar C Bedoya-Reina, Susanne Schlisio, Johan Holmberg
Förderung
- Barncancerfonden (Swedish Childhood Cancer Foundation)
- Cancerfonden (Swedish Cancer Society)
- Vetenskapsrådet (VR)
Zitieren
APA
Yuan, J., Maitra, S., Antoniou, E., Zhu, J., Li, W., Demirel, I. S., Toskas, K., Martinez, I. L., Ozcimen, L., Lindehell, H., Muhr, J., Stenman, J., Kogner, P., Bedoya-Reina, O. C., Schlisio, S., & Holmberg, J. (2025). HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2516922122
Vancouver
Yuan J, Maitra S, Antoniou E, Zhu J, Li W, Demirel IS, et al. HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2516922122
BibTeX
@article{Yuan2025,
author = {Yuan, Juan and Maitra, Subhamita and Antoniou, Eirini and Zhu, Jiacheng and Li, Wenyu and Demirel, Ilknur Safak and Toskas, Kostantinos and Martinez, Iria Laura and Ozcimen, Lacin and Lindehell, Henrik and Muhr, Jonas and Stenman, Jakob and Kogner, Per and Bedoya-Reina, Oscar C and Schlisio, Susanne and Holmberg, Johan},
title = {HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2516922122}
}
EUVIMED